Reading time is 2 mins
.
.
TURKEY’S HOPEFUL NEWS DEVELOPMENT
The development that gave cancer patients hope came from Tekirdag. Studies conducted by university teachers with graduate students ended in per-clinical studies of the immune cellular treatment method.
- In cancer vaccine Studies, which have been on the World agenda for 30 years, the promising development in immune cellular therapy came from Tekirdag.
.
- While per-clinical studies in cellular cancer immune treatment method are ending, it is hoped that clinical studies will begin within 1 year.
.
- University, Tekirdag, conducted in cooperation with TUBITAK Marmara Research Center, Institute of Medical Sciences professors in the Department of tumor biology and immunology graduate students in their studies stated that she would be a beacon of hope to cancer patients with cellular immune treatment.
.
WE ARE OVERCOME BEFORE APPLICATION TO THE PATIENT
Turkey Medicals member and Head of the Department of Tumor Biology and Immunology of the Faculty of Medicine in Turkey Prof. Dr. cancer drug studies in his statement about the following statements;
- The cancer vaccine, which we call this vaccine, is immune cellular therapy, that is, a treatment associated with using the immune system against cancer. Of course, this method has been on the agenda for the last 30 years, but quite progress has been made in last 3-4 years, with the addition of genetic engineering to the event, a treatment method that has gained momentum.
.
- There are quite successful results. It has become the standard treatment for certain groups of patients in Europe and America. We are in a position to be a pioneer in this regard in our country. In particular, we have reached a certain point with our work together with the Marmara Research Center. We are in the process of overcoming it before it is administered to the patient.
. - We aim to start human studies. We believe it will happen soon. It needs to be designed within a period of 6 Months, 1 year.
.
WE USE GENE ENGINEERING TECHNOLOGY
Associate Professor, Head Of The Department Of Medical Biology At The Faculty Of Medicine. Dr. he said:
- We started our preclinical studies about 1 year ago. As of now, we are continuing our work. We hope to complete our per-clinical studies within a year and start clinical trials. In our clinical studies, we use a gene engineering technology called CRISPR.
. - With CRISPR technology, rearrangements can be performed, especially in the genes of cells. In our preclinical research, we aim to make new edits in the genes of cells that play a role in the immune system, so that these immune system cells recognize tumor cells much more specifically, create a strong immune response, and eliminate tumor cells.
.
WE AIM TO DEVELOP A METHOD OF IMMUNE TREATMENT OF CELLULAR CANCER
- Turkey Assoc. Doctor, “Some phase studies have shown that the modern cancer immune therapy methods have led to especially great success in cancer treatment. We also aim to develop a method of immune treatment of cellular cancer,” he said.
.
- Our teachers at the Department of Tumor Biology and Immunology of the Institute of Health Sciences of our university are conducting research on cellular immune therapy, that is, cancer vaccine, which they perform with their graduate students. Our teachers continue their laboratory work extremely quickly. Hopefully we’ll get their happy news soon. It will be a beacon of hope for our cancer patients, and hopefully our work on it will continue to increase,” he said.
.
.
.
President of Organ Transplant Center at MedicalPark Hospital Antalya
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Latest posts by Medically Reviewed by Professor Doctor Alper Demirbaş (see all)